TabletsClinical Overview
Cefixime and Moxifloxacin combination pairs a 3rd-generation oral cephalosporin with a respiratory fluoroquinolone. Provides enhanced dual coverage against typical and atypical respiratory pathogens, resistant Gram-negative bacilli, and anaerobes. Indicated for severe or refractory community-acquired pneumonia, acute exacerbations of chronic bronchitis, and complicated polymicrobial infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, with or without food. Avoid taking antacids, multivitamins with minerals, or iron supplements within 4 hours before or 2 hours after moxifloxacin. Complete the prescribed course.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, diarrhea, headache, dizziness, insomnia. Rare/Severe: QT prolongation and ventricular arrhythmias, tendonitis/tendon rupture, peripheral neuropathy, and severe hepatotoxicity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with known QT prolongation, uncorrected hypokalemia, or myasthenia gravis. Discontinue immediately if tendon pain or neurosensory symptoms occur. Use under strict specialist supervision.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Cefixime Oral Suspension 50mg per 5ml
Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.
Cefixime Tablets 100 mg
Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.
Cefixime Tablets 200 mg
Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.
Cefixime 200mg + Ofloxacin 200mg Tablets
Cefixime and Ofloxacin is a fixed-dose combination antibiotic combining a 3rd-generation cephalosporin and a broad-spectrum fluoroquinolone. Cefixime inhibits cell wall synthesis, while ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, halting DNA replication. This dual mechanism provides synergistic bactericidal coverage against resistant pathogens. Indicated for enteric fever (typhoid fever), severe respiratory tract infections, complicated urinary tract infections, and mixed bacterial pelvic infections.